LifeMD Inc. (LFMD)
NASDAQ (NMS) NASDAQ (NMS) Primary 
AT&T Teams Up With LifeMD for Virtual Health Care: Can it Aid Shares?
T expands customer benefits with complimentary LifeMD memberships, offering virtual care, prescriptions and pharmacy services.
LifeMD: Still Undervalued Despite Earnings Miss
LifeMD remains a Buy despite disappointing Q2 2026 results, with revenue and EBITDA guidance revised downward and a sequential subscriber decline. LFMD's core business model is profitable at an 88% gross margin, but elevated customer acquisition costs—now 59% of revenue—are pressuring EBITDA. Management is shifting strategy from auction-based marketing to partnerships with manufacturers, employers, and insurers, aiming to reduce CAC and leverage branded GLP-1 therapies.
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD Q2 Earnings Call Highlights
LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability.
LifeMD, Inc. (LFMD) Reports Q2 Loss, Lags Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.06 per share a year ago.
LifeMD, Inc. (LFMD) Reports Q1 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to earnings of $0.01 per share a year ago.
LifeMD: Wegovy Pill, Net Cash, And Low Multiple Sets Up Longs For Possible Alpha
LifeMD is rated Buy, trading at a low 0.796x TTM sales, with upside if multiples revert. LFMD's strategic divestment of WorkSimpli refocused the business as a pure-play telehealth and pharmacy provider. The recent launch of the Wegovy pill will expand growth from its GLP-1 vertical.
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.
LifeMD: Still My Favorite Bargain On The Market
LifeMD remains a deeply undervalued telehealth stock, now trading with significant pessimism priced in after a 55% decline. LFMD's business model faces risks from slowing growth, legal issues, competition, and a disappointing WorkSimpli sale, but the fundamental story remains intact. Preferred shares yield just under 10% and offer lower risk, but I favor the common stock for its substantial upside potential at current prices.
LifeMD: Pure Telehealth Play With In-House Pharmacy Integration
LifeMD is rated a buy with an FY 2026 target price of ~$6, implying over 85% upside from current levels. LFMD's shift to a pure-play telehealth model, divesting WorkSimpli, and integrating in-house pharmacy capabilities are expected to drive growth and margin expansion. Regulatory approval for 503-A compounding pharmacy and the Novo Nordisk Wegovy partnership are highlighted as key catalysts for profitability and differentiation.
LifeMD, Inc. (LFMD) Q3 2025 Earnings Call Transcript
LifeMD, Inc. ( LFMD ) Q3 2025 Earnings Call November 17, 2025 4:30 PM EST Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Steven Valiquette - Mizuho Securities USA LLC, Research Division Anderson Schock - B. Riley Securities, Inc., Research Division Sarah James - Cantor Fitzgerald & Co., Research Division Eduardo Martinez-Montes - H.C.
